Viva Biotech Holdings disclosed that it repurchased 2.60 million ordinary shares on 5 June 2026 through on-exchange transactions at prices ranging from HKD 1.19 to HKD 1.22 per share, for a total consideration of HKD 3.14 million.

Including this latest transaction, the company has bought back 25.32 million shares between 8 May and 5 June 2026, representing 1.19% of the 2.13 billion issued shares outstanding on the date of the repurchase mandate (12 June 2025). All repurchased shares are held for cancellation; none has yet been cancelled or re-designated as treasury shares.

The issued share capital remains unchanged at 2.13 billion ordinary shares as of 5 June 2026, as the bought-back shares have not been cancelled. Repurchase prices during the 8 May–5 June period carried volume-weighted averages between HKD 1.21 and HKD 1.57 per share.

Under the existing mandate, Viva Biotech is authorised to repurchase up to 212.84 million shares. Following the cumulative buyback of 25.32 million shares, 187.52 million shares remain available for repurchase. In accordance with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares until 5 July 2026.

The board confirms that all repurchases were conducted in compliance with the Hong Kong Main Board Listing Rules and the company’s shareholder mandate dated 12 June 2025.